GlassScriptPhysician profile
Joseph E Gadzia
NPI 1740260868
$28,195.88
in general payments reported to CMS, 2019-2025
50 companies · $2,276 in 2025
The $2,276 reported for 2025 was more than what 90% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,623 · 2020: $3,308 · 2021: $2,041 · 2022: $2,371 · 2023: $7,602 · 2024: $2,975 · 2025: $2,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,765 · Consulting Fee: $3,803 · Travel and Lodging: $1,102 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,765.08 |
| Consulting Fee | $3,802.50 |
| Travel and Lodging | $1,101.59 |
| Education | $183.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,889.66 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $5,772.96 | 2019-2025 | |
| Abbvie INC. | $2,411.75 | 2019-2025 | |
| Biofrontera INC. | $2,331.71 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $1,540.24 | 2019-2025 | Winlevi, Ilumya, Blu-U |
| Regeneron Healthcare Solutions, INC. | $1,149.85 | 2019-2025 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $1,119.15 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $844.67 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $811.33 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $698.23 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $552.29 | 2019-2025 | |
| Almirall LLC | $468.40 | 2020-2025 | Seysara |
| Organogenesis INC. | $455.56 | 2019-2024 | Puraply |
| Amgen INC. | $434.69 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $371.10 | 2019-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $365.41 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $327.77 | 2019-2023 | Arazlo |
| Prugen, INC. Pharmaceuticals | $300.86 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $292.52 | 2019-2025 | |
| Kerecis Limited | $285.31 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Galderma Laboratories, L.P. | $167.70 | 2019-2025 | Oracea, Nemluvio, Aklief |
| Dermavant Sciences, INC. | $162.72 | 2023-2024 | Vtama |
| Genentech USA, INC. | $159.98 | 2019-2023 | Xolair |
| Convatec INC. | $144.72 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.65 | 2023-2024 | Spevigo, Cyltezo |
| Helsinn Therapeutics (U.S.), INC. | $121.91 | 2019-2025 | Valchlor |
| Stemline Therapeutics INC. | $120.78 | 2021-2022 | |
| Dusa Pharmaceuticals, INC. | $91.15 | 2019 | |
| Mallinckrodt Hospital Products INC. | $77.70 | 2025 | Acthar |
| Organon LLC | $75.72 | 2024-2025 | Vtama, Hadlima |
| Sandoz INC. | $64.63 | 2019-2024 | Hyrimoz |
| Integra Lifesciences Corporation | $56.45 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Vyne Pharmaceuticals INC. | $49.08 | 2020-2021 | |
| Krystal Biotech INC | $45.51 | 2023-2024 | Vyjuvek |
| Janssen Scientific Affairs, LLC | $40.41 | 2023 | Tremfya |
| Strata Skin Sciences, INC. | $38.48 | 2021-2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $32.91 | 2024 | Zoryve |
| Tactile Systems Technology INC | $31.55 | 2021-2022 | |
| Reprise Biomedical, INC. | $25.43 | 2025 | Miro3d |
| Revance Therapeutics, INC. | $23.60 | 2024 | Daxxify |
| Fresenius Kabi USA, LLC | $21.32 | 2023 | Idacio |
| Kyowa Kirin, INC. | $15.74 | 2021 | |
| Journey Medical Corporation | $15.25 | 2019 | |
| Allergan, INC. | $12.40 | 2020 | |
| Celgene Corporation | $12.25 | 2019 | |
| Osiris Therapeutics INC. | $12.24 | 2019 | |
| Aclaris Therapeutics, INC. | $12.14 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gadzia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.